{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:07:57Z","timestamp":1775236077444,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminoncol.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T18:02:17Z","timestamp":1454954537000},"page":"260-264","source":"Crossref","is-referenced-by-count":39,"title":["The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"43","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.02.004_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2011.1.110","article-title":"The treatment of relapsed refractory chronic lymphocytic leukemia","volume":"2011","author":"Brown","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib2","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3109\/10428194.2012.695781","article-title":"Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia","volume":"53","author":"Davids","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib3","doi-asserted-by":"crossref","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","article-title":"p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes","volume":"272","author":"Chantry","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","article-title":"Signalling by PI3K isoforms: insights from gene-targeted mice","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib6","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.287.5455.1049","article-title":"Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation","volume":"287","author":"Hirsch","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib9","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","article-title":"Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing","volume":"173","author":"Reif","year":"2004","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib10","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib13","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u05f3-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib14","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib15","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib16","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib17","first-page":"S88","article-title":"Preliminary Evidence of Clinical Activity in a Phase I Study of CAL-101, a Potent Selective Inhibitor of the p110 Delta Isoform of Phosphatidylinositol-3-Kinase, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"94","author":"Brown","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib19","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib21","volume":"4180","author":"Furman","year":"2013","journal-title":"A Phase 1 Study Of The Selective PI3K\u03b4 Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib22","doi-asserted-by":"crossref","unstructured":"Barrientos J, Coutre S, De Vos S, et al. Long-term follow-up of a phase 1b trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients with relapsed\/refractory (R\/R) CLL including pts with del17p\/TP53 mutation. ASCO Meeting Abstracts 33, abstr 7011 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.7011"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib24","volume":"330","author":"Sharman","year":"2014","journal-title":"Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG\u00ae) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib25","doi-asserted-by":"crossref","unstructured":"Jones J, Wach M, Robak T, et al. Results of a Phase 3 Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (IDELA) in Combination with Ofatumumab (OFA) for Previously Treated Chronic Lymphocytic Leukemia (CLL). ASCO Meeting Abstracts 33, abstr 7023 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.7023"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib26","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Lamanna N, Kipp TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) \u226565 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31, 7005 (2013).","DOI":"10.1200\/jco.2013.31.15_suppl.7005"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib27","first-page":"1","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib28","doi-asserted-by":"crossref","unstructured":"Coutre S, Barrientos J, Brown JR, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. ASCO Meeting Abstracts 33, abstr e18030 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.e18030"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib29","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Flinn I, Patel MR, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed\/refractory lymphoma. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31, 8518 (2013).","DOI":"10.1200\/jco.2013.31.15_suppl.8518"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V122.21.677.677","article-title":"Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-\u03b4,\u03b3, In Patients With Chronic Lymphocytic Leukemia","volume":"122","author":"Flinn","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib31","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V124.21.3334.3334","article-title":"Duvelisib (IPI-145), a PI3K-d,g Inhibitor, Is Clinically Active in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"124","author":"O\u2019Brien","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib32","doi-asserted-by":"crossref","unstructured":"Patel MR, O\u2019Brien SM, Faia K, et al. Early Clinical Activity and Pharmacodynamic Effects of Duvelisib, a PI3K-d,g Inhibitor, in Patients with Treatment-Naive CLL. ASCO Meeting Abstracts 33, 7074 (2014).","DOI":"10.1200\/jco.2015.33.15_suppl.7074"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib33","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood.V124.21.1984.1984","article-title":"TGR-1202, a Novel Once Daily PI3Kd Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma","volume":"124","author":"Burris","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib34","doi-asserted-by":"crossref","unstructured":"Brown JR, Davids MS, Rodon J, et al. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408\/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed\/refractory lymphoma. Clinical Cancer Research. epub ahead of print (2015)","DOI":"10.1158\/1078-0432.CCR-14-3262"},{"key":"10.1053\/j.seminoncol.2016.02.004_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V122.21.86.86","article-title":"SAR245409 Monotherapy In Relapsed\/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study","volume":"122","author":"Brown","year":"2013","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T03:48:07Z","timestamp":1600141687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0093775416000105"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}